zur Navigation zum Inhalt
 
Onkologie 13. Jänner 2016

Gastric and esophageal cancer: Post ASCO 2015

Immunologic tumor therapy was the leading theme of this year’s ASCO. In this context first results for check point inhibitors active in esophageal and gastric cancer were presented. Phase III trials involving c-met inhibitors however were not successful. First phase II results with regorafenib emphasize a potential role for TKI’s in gastric cancer.

Zu diesem Thema wurden noch keine Kommentare abgegeben.

Mehr zum Thema

<< Seite 1 >>

Medizin heute

Aktuelle Printausgaben